- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
New Radiopharmaceutical Approved for Cancer Pain Relief
Q BioMed launches Strontium89 injections for bone-related pain.
A new therapeutic radiopharmaceutical for treating cancer-related pain has been released.
Biotech company Q BioMed announced the release of Strontium89, a U.S. Food and Drug Administration-approved injection of strontium chloride Sr-89 that is intended to alleviate pain associated with cancer that has spread to the bone.
According to results from several multi-center trials, a single injection of Strontium89 performs better than a placebo in patients who have persistent pain after external-beam radiation therapy for bone metastases. Based on the findings, more patients who received Strontium89 reported pain scores of 0. Pain relief lasted between 2-to-5 months for most participants.
Despite the pain relief, the company reported that bone marrow toxicity is possible after Strontium89 injection, so it is not recommended for patients who have significantly compromised bone marrow.
In addition, blood cell count monitoring at least once every two weeks is recommended for patients receiving Strontium89.
Q BioMed plans to deliver order to hospitals this month with full production beginning in March.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
